{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:40:30Z","timestamp":1770990030414,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"S5","license":[{"start":{"date-parts":[[2015,6,7]],"date-time":"2015-06-07T00:00:00Z","timestamp":1433635200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Meda Pharma GmbH & Co. KG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Global Alliance to Improve Outcomes in Acne Group recommends retinoid\u2010based combination therapy as first\u2010line therapy and the preferred treatment approach for almost all acne patients except those with the most severe disease. Clindamycin 1% (as clindamycin phosphate 1.2%)\/tretinoin 0.025% (Clin\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>) is a new fixed\u2010dose retinoid\u2010based combination therapy. The aqueous\u2010based gel formulation of Clin\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> was designed to minimize skin irritation and optimize adherence with the therapy. It contains both solubilized and crystalline tretinoin which allows the retinoid to be slowly released onto the skin surface and decreases the potential for cutaneous irritation. A pooled analysis of three pivotal studies involving 4550 acne patients showed that Clin\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> is well tolerated and effective at treating both inflammatory and non\u2010inflammatory acne lesions. The onset of action of Clin\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> is rapid occurring within 2\u00a0weeks of treatment initiation. It is not associated with acne flaring or an increase in clindamycin\u2010resistant <jats:italic>Propionibacterium acnes<\/jats:italic> counts. Clin\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> is considered as effective as adapalene 0.1%\/benzoyl peroxide (<jats:styled-content style=\"fixed-case\">BPO<\/jats:styled-content>) 2.5%, whereas Clin\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> has a more favourable tolerability profile. Clin\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> may be more effective than clindamycin 1%\/<jats:styled-content style=\"fixed-case\">BPO<\/jats:styled-content> 5% at treating non\u2010inflammatory acne lesions since the latter does not contain a retinoid to target comedones. Clin\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> is also easy for patients to handle and apply, and has the advantage of not containing <jats:styled-content style=\"fixed-case\">BPO<\/jats:styled-content> which can bleach hair and fabrics. Taken together, the profile of Clin\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> suggests Clin\u2010<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> to be a first\u2010line treatment for patients with facial acne.<\/jats:p>","DOI":"10.1111\/jdv.13185","type":"journal-article","created":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T01:34:56Z","timestamp":1433986496000},"page":"8-13","source":"Crossref","is-referenced-by-count":14,"title":["Clindamycin phosphate 1.2% \/ tretinoin 0.025%: a novel fixed\u2010dose combination treatment for acne vulgaris"],"prefix":"10.1111","volume":"29","author":[{"given":"F.","family":"Ochsendorf","sequence":"first","affiliation":[{"name":"Clinic for Dermatology, Venereology and Allergy University Hospital Frankfurt\/Main Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.01.019"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/0128071-200809060-00003"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304020-00001"},{"key":"e_1_2_11_5_1","first-page":"22","article-title":"Tretinoin: a review of its anti\u2010inflammatory properties in the treatment of acne","volume":"4","author":"Schmidt N","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464210-00002"},{"key":"e_1_2_11_7_1","first-page":"405","article-title":"Clindamycin phosphate 1.2%\u2010 tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability","volume":"81","author":"Del Rosso JQ","year":"2008","journal-title":"Cutis"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201694"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018922114398"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.1390s2048.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.34010"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903277228"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1982.tb04238.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07047.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1684\/ejd.2014.2293","article-title":"Efficacy and safety of clindamycin phosphate 1.2%\/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double\u2010blind, parallel\u2010group, phase III studies","volume":"24","author":"Dreno B","year":"2014","journal-title":"Eur J Dermatol"},{"key":"e_1_2_11_16_1","first-page":"607","article-title":"Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris","volume":"6","author":"Schlessinger J","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_11_17_1","first-page":"31","article-title":"Clindamycin 1.2% tretinoin 0.025% gel versus clindamycin gel treatment in acne patients: a focus on Fitzpatrick skin types","volume":"4","author":"Schmidt N","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_11_18_1","first-page":"619","article-title":"A phase IV, open\u2010label study evaluating the use of triple\u2010combination therapy with minocycline HCl extended\u2010release tablets, a topical antibiotic\/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris","volume":"12","author":"Zaenglein AL","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_11_19_1","article-title":"Onset of action and efficacy of novel clindamycin 1%\/tretinoin 0.025% formulation for acne vulgaris","volume":"68","author":"Dreno B","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2006.00078.x"},{"key":"e_1_2_11_21_1","first-page":"358","article-title":"Safety of a novel gel formulation of clindamycin phosphate 1.2%\u2010tretinoin 0.025%: results from a 52\u2010week open\u2010label study","volume":"82","author":"Kircik LH","year":"2008","journal-title":"Cutis"},{"key":"e_1_2_11_22_1","first-page":"15","article-title":"A review of the anti\u2010inflammatory properties of clindamycin in the treatment of acne vulgaris","volume":"85","author":"Del Rosso JQ","year":"2010","journal-title":"Cutis"},{"key":"e_1_2_11_23_1","first-page":"41","article-title":"Retinoid\u2010induced flaring in patients with acne vulgaris: does it really exist?: A discussion of data from clinical studies with a gel formulation of clindamycin phosphate 1.2% and tretinoin 0.025%","volume":"1","author":"Del Rosso JQ","year":"2008","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_11_24_1","first-page":"799","article-title":"Do topical retinoids cause acne to \u201cflare\u201d?","volume":"8","author":"Yentzer BA","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_11_25_1","first-page":"151","article-title":"A novel gel formulation of clindamycin phosphate\u2010tretinoin is not associated with acne flaring","volume":"82","author":"Leyden JJ","year":"2008","journal-title":"Cutis"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05067.x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04270.x"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04506.x"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04374.x"},{"key":"e_1_2_11_30_1","first-page":"131","article-title":"A randomized, investigator\u2010blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%\/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%\/tretinoin 0.025% gel in the topical treatment of acne vulgaris","volume":"9","author":"Jackson JM","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80023-6"},{"key":"e_1_2_11_32_1","first-page":"1434","article-title":"In vivo antibacterial effects of tretinoin\u2010clindamycin and clindamycin alone on Propionibacterium acnes with varying clindamycin minimum inhibitory","volume":"11","author":"Leyden JJ","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_11_33_1","article-title":"Cross\u2010study comparison of efficacy and safety of clindamycin 1%\/tretinoin 0.025% and adapalene 0.1%\/benzoyl peroxide 2.5% for acne vulgaris","volume":"68","author":"Perez M","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_11_34_1","unstructured":"Duac.Summary of product characteristics.Stiefel (a GlaxoSmithKline Company) UK 2011."},{"key":"e_1_2_11_35_1","first-page":"1422","article-title":"A double\u2010blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin\/tretinoin and benzoyl peroxide\/adapalene","volume":"11","author":"Goreshi R","year":"2012","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13185","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T08:08:59Z","timestamp":1694592539000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":34,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/jdv.13185"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13185","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}